Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 8 · newest first

  1. Novel approaches to combat chemoresistance against glioblastomasCancer Drug Resistance · 2020
  2. Evaluation of the reducing potential of PSMA-containing endosomes by FRET imagingCancer Drug Resistance · 2020
  3. Targeting IKKα kinase to prevent tumor progression and therapy resistanceCancer Drug Resistance · 2020
  4. Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistanceCancer Drug Resistance · 2020
  5. Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cellsCancer Drug Resistance · 2020
  6. The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsiesCancer Drug Resistance · 2020
  7. Nanotechnological approaches for counteracting multidrug resistance in cancerCancer Drug Resistance · 2020
  8. Effects of DNA topoisomerase IIα splice variants on acquired drug resistanceCancer Drug Resistance · 2020
  9. Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?Cancer Drug Resistance · 2020
  10. Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patientsCancer Drug Resistance · 2020
  11. “Pharmacogenetics of Cancer” - Cancer Drug Resistance special issueCancer Drug Resistance · 2020
  12. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinomaCancer Drug Resistance · 2020
  13. Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?Cancer Drug Resistance · 2020
  14. Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancerCancer Drug Resistance · 2020
  15. Intracrine androgen biosynthesis and drug resistanceCancer Drug Resistance · 2020
  16. 3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAsCancer Drug Resistance · 2020
  17. Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathwaysCancer Drug Resistance · 2020
  18. A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapyCancer Drug Resistance · 2020
  19. Drug resistance in glioblastoma: are persisters the key to therapy?Cancer Drug Resistance · 2020
  20. Molecular mechanisms of docetaxel resistance in prostate cancerCancer Drug Resistance · 2020
  21. Improving TRAIL-induced apoptosis in cancers by interfering with histone modificationsCancer Drug Resistance · 2020
  22. Cancer stem cells, plasticity, and drug resistanceCancer Drug Resistance · 2020
  23. MicroRNA and liver cancerCancer Drug Resistance · 2020
  24. Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetiteCancer Drug Resistance · 2020
  25. Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patientsCancer Drug Resistance · 2020
  26. Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathwayCancer Drug Resistance · 2020
  27. Methods for extracellular vesicle isolation from cancer cellsCancer Drug Resistance · 2020
  28. MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expressionCancer Drug Resistance · 2020
  29. Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistanceCancer Drug Resistance · 2020
  30. Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxelCancer Drug Resistance · 2020
  31. Kinase inhibitors: look beyond the label on the bottleCancer Drug Resistance · 2019
  32. Drug resistance and combating drug resistance in cancerCancer Drug Resistance · 2019
  33. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteinsCancer Drug Resistance · 2019
  34. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulatorsCancer Drug Resistance · 2019
  35. Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitorsCancer Drug Resistance · 2019
  36. Influence of lysosomal sequestration on multidrug resistance in cancer cellsCancer Drug Resistance · 2019
  37. Opportunities and challenges of implementing Pharmacogenomics in cancer drug developmentCancer Drug Resistance · 2019
  38. Perspective: plasticity, the enemy of the goodCancer Drug Resistance · 2019
  39. Pharmacogenetics of anticancer monoclonal antibodiesCancer Drug Resistance · 2019
  40. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patientsCancer Drug Resistance · 2019
  41. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignanciesCancer Drug Resistance · 2019
  42. Dodging the bullet: therapeutic resistance mechanisms in pediatric cancersCancer Drug Resistance · 2019
  43. Cell-mediated immune resistance in cancerCancer Drug Resistance · 2019
  44. Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1Cancer Drug Resistance · 2019
  45. RET in breast cancer: pathogenic implications and mechanisms of drug resistanceCancer Drug Resistance · 2019
  46. Stress and drug resistance in cancerCancer Drug Resistance · 2019
  47. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapiesCancer Drug Resistance · 2019
  48. Topoisomerase IB: a relaxing enzyme for stressed DNACancer Drug Resistance · 2019
  49. Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathwaysCancer Drug Resistance · 2019
  50. Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoproteinCancer Drug Resistance · 2019